{"id":104200,"date":"2025-11-18T20:42:45","date_gmt":"2025-11-18T20:42:45","guid":{"rendered":"https:\/\/www.mymsd.ch\/it\/?p=104200"},"modified":"2026-03-02T14:38:16","modified_gmt":"2026-03-02T14:38:16","slug":"follow-up-esmo-2025","status":"publish","type":"post","link":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/follow-up-esmo-2025\/","title":{"rendered":"Aggiornamento dall\u2019ESMO 2025"},"content":{"rendered":"\n<figure class=\"wp-block-image aligncenter size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1000\" height=\"250\" src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/11\/ESMO-2025.jpg\" alt=\"\" class=\"wp-image-104199\" srcset=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/11\/ESMO-2025.jpg 1000w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/11\/ESMO-2025.jpg?resize=300,75 300w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/11\/ESMO-2025.jpg?resize=768,192 768w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/11\/ESMO-2025.jpg?resize=320,80 320w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/11\/ESMO-2025.jpg?resize=120,30 120w\" sizes=\"auto, (max-width: 1000px) 100vw, 1000px\" \/><\/figure>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--59a75833c0eeeba4d59f04e9d4bf6f46\"><mark class=\"has-inline-color has-teal-color\"><mark class=\"has-inline-color has-teal-color\">Il congresso ESMO 2025 ha portato importante nuove conoscenze per il trattamento del cancro. Scopra qui i principali risultati di follow-up dei nostri studi KEYNOTE, presentati in modo chiaro e sintetico.<\/mark><\/mark><\/h3>\n\n\n\n<div style=\"height:24px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--bb4aa9cd86e3898458cf8b3f197c54a0 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--bb4ac46c709e6eb7bd718500c3999298 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--def84b6d494868d61ecc4f704357d26e mhh-mcn-v1-columns mhh-mcn-columns--gutter-custom\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--9010be4a40068e2b212d227c242207b9 mhh-mcn-column mhh-mcn-column--6 mhh-mcn-column--m-6 mhh-mcn-column--l-6\">\n    \n\n<p class=\"has-white-color has-text-color has-border-color has-has-red-border-color-border-color mhh-mcn-v1-paragraph--left  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--c584729b8195450a15bc81d53120a872 wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"240\" height=\"240\" class=\"wp-image-94043\" style=\"width: 80px\" src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2021\/06\/Melanom.png\" alt=\"\" srcset=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2021\/06\/Melanom.png 240w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2021\/06\/Melanom.png?resize=150,150 150w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2021\/06\/Melanom.png?resize=120,120 120w\" sizes=\"auto, (max-width: 240px) 100vw, 240px\" \/><\/p>\n\n<\/div>\n\n\n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--605da8c1502bc19542b90ea6d792001f mhh-mcn-column mhh-mcn-column--6 mhh-mcn-column--m-6 mhh-mcn-column--l-6\">\n    \n\n<p class=\"has-black-color has-text-color has-border-color has-has-red-border-color-border-color mhh-mcn-v1-paragraph--left  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--d207bf9d69b5640dba489ce761aaf090 wp-block-paragraph\"><strong><strong>Trattamento adiuvante con KEYTRUDA\u00ae per il melanoma in stadio II<\/strong><br><strong>KEYNOTE-716<sup>1<\/sup><\/strong><\/strong><\/p>\n\n<\/div>\n\n\n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--0ee5be03119706a5eeb78563cfe8f99f mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n<figure class=\"wp-block-table mhh-mcn-v1-table mhh-mcn-v1-table--be2cc26124acd731d30c9b03500fac23\"><table class=\"has-fixed-layout\"><tbody><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong>Follow-up mediano<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">5 anni<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong>RFS mediana<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">HR 0.62 (IC al 95 %: 0.50-0.76)<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong>DMFS (endpoint secondario)<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">DMFS: HR 0.59 (IC al 95 %: 0.46-0.77)<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong><strong>PRFS2<\/strong> (<strong>endpoint secondario<\/strong>)<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">PRFS2: HR 0.72 (IC al 95 %: 0.55-0.94)<\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n\n\n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--eb921251a61a8c970217dca11051b6e1 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<div style=\"height:24px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ac87a9c51cb07c2f0bd69d043d5ce2c1 wp-block-paragraph\">Dopo un follow-up mediano di oltre 5 anni (64.7 mesi), nel melanoma in stadio II, KEYTRUDA\u00ae ha continuato a mostrare un miglioramento clinicamente significativo della RFS (rischio di recidiva) e della DMFS (rischio di metastasi a distanza) rispetto al placebo.<sup>1<\/sup><\/p>\n\n<\/div>\n\n\n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--209067c084a016315d6dba2e0004bb08 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<div style=\"height:24px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--b1880cfdfdeeb81624de34b5075738d3\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--9b085d35ad50bccb602e87e9fce22a33 mhh-mcn-v1-link--is-variation mhh-mcn-v1-link--button-primary\" href=\"https:\/\/www.mymsd.ch\/it\/products\/keytruda\/indicazioni\/melanom\/\" target=\"_self\">\n                    <span class=\"mhh-mcn-v1-link__label\">Trattamenti con KEYTRUDA\u00ae per il melanoma<\/span>\n                <\/a><\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<div style=\"height:24px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<div style=\"height:48px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--aae260be58c53a0d546ca665c9658cef mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--e4d8da0396fe7d18b229f0ff8dafe008 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--51841b44e6af9e0c27e1538d82aaf038 mhh-mcn-v1-columns mhh-mcn-columns--gutter-custom\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--8109050dae283101bb453a3c217fc4a7 mhh-mcn-column mhh-mcn-column--6 mhh-mcn-column--m-6 mhh-mcn-column--l-6\">\n    \n\n<p class=\"has-white-color has-text-color has-border-color has-has-red-border-color-border-color mhh-mcn-v1-paragraph--left  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--acb4f10ba06b10ca660e14989ba862ca wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"240\" height=\"240\" class=\"wp-image-94042\" style=\"width: 80px\" src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2021\/06\/Lungenkarzinom.png\" alt=\"\" srcset=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2021\/06\/Lungenkarzinom.png 240w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2021\/06\/Lungenkarzinom.png?resize=150,150 150w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2021\/06\/Lungenkarzinom.png?resize=120,120 120w\" sizes=\"auto, (max-width: 240px) 100vw, 240px\" \/><\/p>\n\n<\/div>\n\n\n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--76ac33b7833ba03b02e139847774e720 mhh-mcn-column mhh-mcn-column--6 mhh-mcn-column--m-6 mhh-mcn-column--l-6\">\n    \n\n<p class=\"has-black-color has-text-color has-border-color has-has-red-border-color-border-color mhh-mcn-v1-paragraph--left  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ecde939bd8a93dcf8f18a8478f8eb327 wp-block-paragraph\"><strong>Trattamento perioperatorio con KEYTRUDA\u00ae nel NSCLC resecabile in stadio precoce<br><strong>KEYNOTE-671<sup>2<\/sup><\/strong><\/strong><\/p>\n\n<\/div>\n\n\n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--53548eda966862689a58bb90cdd46316 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n<figure class=\"wp-block-table mhh-mcn-v1-table mhh-mcn-v1-table--f4c58f937eabc21ba9e10be9b47862ac\"><table class=\"has-fixed-layout\"><tbody><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong>Follow-up mediano<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">5 anni<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong><strong>O<\/strong>S mediana<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\"><strong>NR<\/strong> con KEYTRUDA\u00ae rispetto a 70.7 mesi (IC al 95 %: 53.7-NR)<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong>EFS mediana<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\"><strong>57.1 mesi<\/strong> (IC al 95 %: 38.0-NR) con KEYTRUDA\u00ae rispetto a 18.4 mesi (IC al 95 %: 14.8-22.1)<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong><strong>OS<\/strong><\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">HR: 0.74 (IC al 95 %: 0.59-0.92)<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\"><strong>EFS<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">HR: 0.58 (IC al 95 %: 0.48-0.69)<\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n\n\n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--cede1836ab592957340ada80ac11cc14 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<div style=\"height:24px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--691d70d86de569fba80e395b69ba10f3 wp-block-paragraph\">Con un follow-up di 5 anni, il trattamento perioperatorio con KEYTRUDA\u00ae pi\u00f9 chemioterapia neoadiuvante ha continuato a mostrare dei miglioramenti clinicamente significativi nella sopravvivenza globale (OS) e nella sopravvivenza libera da eventi (EFS) rispetto alla sola chemioterapia neoadiuvante, che sono stati mantenuti nel tempo in pazienti con NSCLC in fase iniziale.<sup>2<\/sup><\/p>\n\n<\/div>\n\n\n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--21011a73cfce60b0fd3f735a5dd5f029 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<div style=\"height:24px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--24bdf8236f1b7f398fd3a28977500f21\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--5b5f2a2f0260090ce9742a21600d6e50 mhh-mcn-v1-link--is-variation mhh-mcn-v1-link--button-primary\" href=\"https:\/\/www.mymsd.ch\/it\/products\/keytruda\/indicazioni\/tc\/\" target=\"_self\">\n                    <span class=\"mhh-mcn-v1-link__label\">Trattamenti con KEYTRUDA\u00ae per i tumori toracici<\/span>\n                <\/a><\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<div style=\"height:24px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<div style=\"height:48px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div style=\"height:50px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\r\n<div class=\"inpsyde-iframe is-responsive has-transparent-background-color\">\r\n    <iframe loading=\"lazy\" height=\"400\" referrerpolicy=\"no-referrer-when-downgrade\" title=\"Questo contenuto \u00e8 stato rilevante per Lei?\" src=\"https:\/\/go.screver.com\/msd-ch-cx\/newsroom-articles?lang=it&amp;hideHeader=true\" width=\"100%\"><\/iframe>\r\n<\/div>\n\n\n<nav class=\"wp-block-mconnect-theme-related-content has-background has-light-grey-background-color\">\n\t<div class=\"wp-block-mconnect-theme-related-content__container\">\n\t\t\t\t\t<h3 class=\"wp-block-mconnect-theme-related-content__title\">\n\t\t\t\tContenuti simili\t\t\t<\/h3>\n\t\t\n\t\t\t\t\t<ul class=\"is-grid-layout has-columns has-three-columns has-top-vertical-alignment\">\n\t\t\t\t\n\t<li class=\"grid-item\">\n\t\t<article\n    class=\"content-item content-item-type-post is-display-media-style has-featured-image has-background has-white-background-color has-link post-103605 post type-post status-publish format-standard has-post-thumbnail hentry category-onco-news-it category-oncology tag-hnscc tag-keytruda\">\n\t\t\t<div class=\"content-item__media-container\">\n\t\t\t<div class=\"content-media\">\n\t\t\t\t<div class=\"content-media__inner\">\n\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"635\" height=\"475\" src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/10\/I-KN689-ONR-Teaser.jpg?w=635&amp;h=475&amp;crop=1\" class=\"content-media__image\" alt=\"\" srcset=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/10\/I-KN689-ONR-Teaser.jpg 1536w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/10\/I-KN689-ONR-Teaser.jpg?resize=300,224 300w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/10\/I-KN689-ONR-Teaser.jpg?resize=768,575 768w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/10\/I-KN689-ONR-Teaser.jpg?resize=1024,766 1024w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/10\/I-KN689-ONR-Teaser.jpg?resize=320,239 320w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/10\/I-KN689-ONR-Teaser.jpg?resize=120,90 120w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/10\/I-KN689-ONR-Teaser.jpg?resize=180,135 180w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/10\/I-KN689-ONR-Teaser.jpg?resize=635,475 635w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/10\/I-KN689-ONR-Teaser.jpg?resize=1400,1047 1400w\" sizes=\"auto, (max-width: 635px) 100vw, 635px\" \/>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\n    \n    <div class=\"content-item__content-container\">\n\t\t<div class=\"content-item__content-body\">\n\t\t\t\t\t\t\t\t\t\t<span\n\t\t\t\t\tclass=\"content-item__primary-tag\"\n\t\t\t\t\ttitle=\"L&#039;elemento \u00e8 stato taggato come: Keytruda\"\n\t\t\t\t>\n\t\t\t\t\tKeytruda\t\t\t\t<\/span>\n\t\t\t\t\t\t<header class=\"content-item__header\">\n\t\t\t\t<span\n\t\t\t\t\tclass=\"content-item__content-type content-type  content-type--post\">\n\t\t\t\t\t<span class=\"content-type__icon\">\n                                            <\/span>\n\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t<h2 class=\"content-item__title\" data-enterprise-id=\"currentHeader\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/keytruda-come-opzione-terapeutica-perioperatoria-per-lhnscc\/\"\n                            class=\"content-item__title-link\"\n                            target=\"_self\"\n                            rel=\"\"\n\t\t\t\t\t\t\t              >\n                            NOVIT\u00c0: KEYTRUDA\u00ae omologato come opzione terapeutica perioperatoria per l\u2019HNSCC con CPS \u2265 1                        <\/a>\n\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\t\t\t<\/header>\n\t\t\t\t\t\t\t<p class=\"content-item__excerpt\">Swissmedic ha omologato KEYTRUDA\u00ae in un&#8217;ulteriore indicazione per il trattamento dell\u2019HNSCC.<\/p>\n\t\t\t\n                                            <div class=\"content-item__content-meta badge-container\">                                                                <div class=\"content-item__dates badge badge--flat badge--dates\">\n                                                        <span class=\"content-item__dates--start badge--dates__start\">\n                                Ottobre 27, 2025                            <\/span>\n                                                                                                        <\/div>\n                                                                            <\/div>\n                \t\t<\/div>\n\t\t<div class=\"content-item__content-footer\">\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t<\/div>\n\n    <\/article>\n\t<\/li>\n\t\n\n\t<li class=\"grid-item\">\n\t\t<article\n    class=\"content-item content-item-type-post is-display-media-style has-featured-image has-background has-white-background-color has-link post-101882 post type-post status-publish format-standard has-post-thumbnail hentry category-onco-news-it category-oncology tag-keytruda tag-melanoma\">\n\t\t\t<div class=\"content-item__media-container\">\n\t\t\t<div class=\"content-media\">\n\t\t\t\t<div class=\"content-media__inner\">\n\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"635\" height=\"475\" src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Teaser-Melanoma-SGDV_2.jpg?w=635&amp;h=475&amp;crop=1\" class=\"content-media__image\" alt=\"Melanoma: il rischio di recidiva pu\u00f2 essere ridotto con l&#039;immunoterapia\" srcset=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Teaser-Melanoma-SGDV_2.jpg?resize=180,135 180w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/03\/I-Teaser-Melanoma-SGDV_2.jpg?resize=635,475 635w\" sizes=\"auto, (max-width: 635px) 100vw, 635px\" \/>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\n    \n    <div class=\"content-item__content-container\">\n\t\t<div class=\"content-item__content-body\">\n\t\t\t\t\t\t\t\t\t\t<span\n\t\t\t\t\tclass=\"content-item__primary-tag\"\n\t\t\t\t\ttitle=\"L&#039;elemento \u00e8 stato taggato come: Melanoma\"\n\t\t\t\t>\n\t\t\t\t\tMelanoma\t\t\t\t<\/span>\n\t\t\t\t\t\t<header class=\"content-item__header\">\n\t\t\t\t<span\n\t\t\t\t\tclass=\"content-item__content-type content-type  content-type--post\">\n\t\t\t\t\t<span class=\"content-type__icon\">\n                                            <\/span>\n\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t<h2 class=\"content-item__title\" data-enterprise-id=\"currentHeader\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/melanoma-il-rischio-di-recidiva-puo-essere-ridotto-con-limmunoterapia\/\"\n                            class=\"content-item__title-link\"\n                            target=\"_self\"\n                            rel=\"\"\n\t\t\t\t\t\t\t              >\n                            Melanoma: il rischio di recidiva pu\u00f2 essere ridotto con l\u2019immunoterapia                        <\/a>\n\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\t\t\t<\/header>\n\t\t\t\t\t\t\t<p class=\"content-item__excerpt\">Molti\/e pazienti con melanoma in stadio IIB e IIC non possono essere guariti\/e solo con la resezione.<\/p>\n\t\t\t\n                                            <div class=\"content-item__content-meta badge-container\">                                                                <div class=\"content-item__dates badge badge--flat badge--dates\">\n                                                        <span class=\"content-item__dates--start badge--dates__start\">\n                                Marzo 28, 2025                            <\/span>\n                                                                                                        <\/div>\n                                                                            <\/div>\n                \t\t<\/div>\n\t\t<div class=\"content-item__content-footer\">\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t<\/div>\n\n    <\/article>\n\t<\/li>\n\t\n\n\t<li class=\"grid-item\">\n\t\t<article\n    class=\"content-item content-item-type-post is-display-media-style has-featured-image has-background has-white-background-color has-link post-49684 post type-post status-publish format-standard has-post-thumbnail hentry category-onco-news-it tag-msd-services\">\n\t\t\t<div class=\"content-item__media-container\">\n\t\t\t<div class=\"content-media\">\n\t\t\t\t<div class=\"content-media__inner\">\n\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"635\" height=\"475\" src=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2023\/01\/hero_empathy-white_lo_96dpi.jpg?w=635&amp;h=475&amp;crop=1\" class=\"content-media__image\" alt=\"Utilizza gi\u00e0 i moduli di richiesta di rimborso dei costi di KEYTRUDA\u00ae?\" srcset=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2023\/01\/hero_empathy-white_lo_96dpi.jpg?resize=180,135 180w, https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2023\/01\/hero_empathy-white_lo_96dpi.jpg?resize=635,475 635w\" sizes=\"auto, (max-width: 635px) 100vw, 635px\" \/>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\n    \n    <div class=\"content-item__content-container\">\n\t\t<div class=\"content-item__content-body\">\n\t\t\t\t\t\t\t\t\t\t<span\n\t\t\t\t\tclass=\"content-item__primary-tag\"\n\t\t\t\t\ttitle=\"L&#039;elemento \u00e8 stato taggato come: MSD Services\"\n\t\t\t\t>\n\t\t\t\t\tMSD Services\t\t\t\t<\/span>\n\t\t\t\t\t\t<header class=\"content-item__header\">\n\t\t\t\t<span\n\t\t\t\t\tclass=\"content-item__content-type content-type  content-type--post\">\n\t\t\t\t\t<span class=\"content-type__icon\">\n                                            <\/span>\n\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t<h2 class=\"content-item__title\" data-enterprise-id=\"currentHeader\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/moduli-di-richiesta-di-rimborso-dei-costi-di-keytruda\/\"\n                            class=\"content-item__title-link\"\n                            target=\"_self\"\n                            rel=\"\"\n\t\t\t\t\t\t\t              >\n                            Utilizza gi\u00e0  i moduli di richiesta di rimborso dei costi di KEYTRUDA\u00ae?                        <\/a>\n\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\t\t\t<\/header>\n\t\t\t\t\t\t\t<p class=\"content-item__excerpt\">Il numero in continuo aumento delle indicazioni per KEYTRUDA\u00ae omologate da Swissmedic rende difficile sapere sempre quali indicazioni sono rimunerate e se si debba tenere conto di ulteriori limitatio dell\u2019elenco delle specialit\u00e0.<\/p>\n\t\t\t\n                                            <div class=\"content-item__content-meta badge-container\">                                                                <div class=\"content-item__dates badge badge--flat badge--dates\">\n                                                        <span class=\"content-item__dates--start badge--dates__start\">\n                                Febbraio 5, 2024                            <\/span>\n                                                                                                        <\/div>\n                                                                            <\/div>\n                \t\t<\/div>\n\t\t<div class=\"content-item__content-footer\">\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t<\/div>\n\n    <\/article>\n\t<\/li>\n\t\n\t\t\t<\/ul>\n\t\t\t<\/div>\n<\/nav>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--2593bddc149557cfb4ee153acebeb639 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--84b098edc6ac618761a19b88981e3f88 mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<h6 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--bb5c2751a8af1d3a0bddee9ffad9f4e7\"><strong><mark class=\"has-inline-color has-black-color\"><em>Abbreviazioni:<\/em><\/mark><\/strong><\/h6>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--1585cecd5b5f513ea7080e411618e541 wp-block-paragraph\"><em><strong>EFS<\/strong>: <em>sopravvivenza libera da<\/em><\/em> eventi <em>(event-free survival<\/em>)<em>; <strong>DMFS<\/strong>: sopravvivenza libera da metastasi a distanza (distant metastasis-free survival); <strong>ESMO<\/strong>: European Society for Medical Oncology; <strong>HR<\/strong>: Hazard Ratio; <strong>IC<\/strong>: Intervallo di confidenza; <strong>PRFS2<\/strong>: sopravvivenza libera da progressione o recidiva 2 (progression\/recurrence-free survival 2); <strong>OS<\/strong>: <em>sopravvivenza globale<\/em> (overall survival); <strong>RFS<\/strong>: sopravvivenza libera da recidive (recurrence-free survival).<\/em><\/p>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--fad7077e76e812148d26d20ace009dc1 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--95aa45728384cc1f06c8110a2ae52d9d mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-12 mhh-mcn-column--l-12\">\n    \n\n<h6 class=\"wp-block-heading has-border-color has-has-red-border-color-border-color  mhh-mcn-v1-heading mhh-mcn-v1-heading--5436a42d990cf2fa945f628fbf125590\"><strong><mark class=\"has-inline-color has-black-color\"><em><strong><em><mark>Riferimenti bibliografici<\/mark><\/em><\/strong>:<\/em><\/mark><\/strong><\/h6>\n\n\n\n<ol class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--aeb4eb92015900b1fab204af3abe6fa0 mhh-mcn-list mhh-mcn-v2-clist--ordered mhh-mcn-v2-clist--ordered-decimal\" dir=\"ltr\" lang=\"en-US\" start=\"1\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <em>Pembrolizumab Versus Placebo as Adjuvant Therapy for Resected Stage IIB or IIC Melanoma: 5-Year Follow-Up of the Phase 3 KEYNOTE-716 Study  (Dr. Alexander Eggermont, ESMO 2025, poster presentation, #1611P, Monday, October 20)<br><strong><strong>Disegno dello studio<\/strong> KEYNOTE-716<\/strong>: studio di fase III multicentrico, in doppio cieco, randomizzato, controllato con placebo (parte 1 in cieco, parte 2 rechallenge\/crossover in aperto): 976 pazienti (\u2265 12 anni) con melanoma in stadio IIB o IIC completamente resecato (popolazione ITT), randomizzazione (1:1): KEYTRUDA\u00ae 200 mg o 2 mg\/kg di peso corporeo fino a un massimo di 200 mg (pazienti padiatrici \u2265 12 anni) ogni 3 settimane (n = 487)* rispetto al placebo (n = 489). Trattamento dei pazienti inizialmente fino a 1 anno o fino alla comparsa di recidiva o tossicit\u00e0 inaccettabile (Parte 1), in caso di recidiva trattamento rechallenge (Parte 2) fino a 2 anni fino alla comparsa di una recidiva o tossicit\u00e0 inaccettabile. Pazienti che a parte l&#8217;operazione avevano ricevuto in precedenza un altro trattamento del melanoma sono stati esclusi dallo studio. Endpoint primario: sopravvivenza libera da recidiva (RFS) nella popolazione complessiva. La RFS \u00e8 stata valutata dallo sperimentatore ed \u00e8 stata definita come il tempo trascorso tra la data di randomizzazione e la data della comparsa della prima recidiva (locale, regionale o metastasi a distanza) o del decesso, a seconda di quale evento si sia verificato per primo. *Per informazioni dettagliate sul dosaggio, consultare l&#8217;informazione professionale.<\/em>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <em>Perioperative pembrolizumab in early-stage non-small- cell lung cancer (NSCLC): 5-year follow-up from KEYNOTE- 671 (Dr. Heather Wakelee, ESMO 2025, Mini oral session 2: Non-metastatic NSCLC, Monday, October 20)<br><strong><em><strong><strong>Disegno dello studio<\/strong><\/strong><\/em> KEYNOTE-671<\/strong>: Studio di fase 3, randomizzato, in doppio cieco, multicentrico, controllato con placebo, per valutare KEYTRUDA\u00ae neoadiuvante pi\u00f9 chemioterapia seguito da KEYTRUDA\u00ae adiuvante come monoterapia rispetto a placebo neoadiuvante pi\u00f9 chemioterapia seguito da trattamento adiuvante con placebo in pazienti con NSCLC resecabile in stadio II, IIIA o IIIB (N2) secondo l\u2019AJCC 8a edizione. Principali criteri di inclusione: pazienti con NSCLC in stadio II, IIIA o IIIB (N2) non trattato in precedenza e resecabile secondo l\u2019AJCC 8a edizione, indipendentemente dall\u2019espressione di PD-L1. Principali criteri di esclusione: malattie autoimmuni attive che hanno richiesto una terapia sistemica entro 2 anni dall\u2019inizio del trattamento; una condizione medica che abbia richiesto una immunosoppressione. Endpoint primari: OS e EFS. Selezione di endpoint secondari: pCR e mPR. Lo studio ha incluso 797 pazienti che dopo randomizzazione (1:1) hanno ricevuto KEYTRUDA\u00ae (200 mg e. v. Q3W per un massimo di 4 cicli) pi\u00f9 chemioterapia (cisplatino [75 mg\/m<sup>2<\/sup> e. v. Q3W, somministrato il giorno 1 di ogni ciclo di 21 giorni] e gemcitabina [1 000 mg\/m<em><sup>2<\/sup><\/em> e. v., somministrata i giorni 1 e 8 di ogni ciclo di 21 giorni] o pemetrexed [500 mg\/m<em><sup>2<\/sup><\/em> e.v., somministrato il giorno 1 di ogni ciclo di 21 giorni]) come terapia neoadiuvante prima dell\u2019operazione, seguita da KEYTRUDA\u00ae (200 mg e. v. Q3W per un massimo di 13 cicli) come terapia adiuvante dopo l\u2019operazione, oppure placebo (e. v. Q3W per un massimo di 4 cicli) pi\u00f9 chemioterapia (cisplatino [75 mg\/m<em><sup>2<\/sup><\/em> e. v. Q3W, somministrato il giorno 1 di ogni ciclo di 21 giorni] e gemcitabina [1 000 mg\/m<em><sup>2<\/sup><\/em> e. v., somministrata i giorni 1 e 8 di ogni ciclo di 21 giorni] o pemetrexed [500 mg\/m<em><sup>2<\/sup><\/em> e. v., somministrato il giorno 1 di ogni ciclo di 21 giorni]) come terapia neoadiuvante prima dell\u2019operazione, seguita da placebo (e. v. Q3W per un massimo di 13 cicli) come terapia adiuvante dopo l\u2019operazione. Il trattamento \u00e8 continuato fino al completamento (17 cicli), ad una progressione della malattia che abbia precluso un intervento chirurgico definitivo, ad una recidiva della malattia nella fase adiuvante, ad una progressione della malattia in pazienti che non erano stati sottoposti ad intervento chirurgico o che avevano avuto una resezione incompleta e sono entrati nella fase adiuvante, o ad una tossicit\u00e0 inaccettabile.<\/em>    <\/li>\n\n<\/ol>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<p dir=\"ltr\" lang=\"it-IT\" class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--6d0513bbcf8a3e7fe36b05aeb0c74d0f wp-block-paragraph\"><mark class=\"has-inline-color has-black-color\"><em><em><em><em>In caso di bisogno, copie degli studi possono essere richieste all\u2019indirizzo<\/em><\/em><\/em><\/em> <em><em><a href=\"mailto:dpoc.switzerland@msd.com\"><em>dpoc.switzerland@msd.com<\/em><\/a>.<\/em><\/em><\/mark><\/p>\n\n\n\n<p dir=\"ltr\" lang=\"it-IT\" class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--7cbbcd56db06d5dcb3a4ff91814309fc wp-block-paragraph\"><mark class=\"has-inline-color has-black-color\"><em><em><em><em><em>Prima della prescrizione, consulti l\u2019informazione professionale completa pubblicata su<\/em><\/em><\/em><\/em><\/em> <em><em><em><em><em><em><a href=\"https:\/\/www.swissmedicinfo-pro.ch\/showText.aspx?textType=FI&amp;lang=IT&amp;authNr=66231&amp;supportMultipleResults=1\" target=\"_blank\" rel=\"noreferrer noopener\">www.swissmedicinfo-pro.ch<\/a><\/em><\/em><\/em><\/em>.<\/em><\/em><\/mark><\/p>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--a92e78568121cacb69df53e5338bb11d\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--ed481f305d99e8bde247830fb852bf59 mhh-mcn-v1-link--is-variation mhh-mcn-v1-link--button-primary\" href=\"https:\/\/www.swissmedicinfo-pro.ch\/showText.aspx?textType=FI&#038;lang=IT&#038;authNr=66231&#038;supportMultipleResults=1\" target=\"_blank\" rel=\"noopener noreferrer\" aria-label=\"Informazione professionale di KEYTRUDA\u00ae\">\n                    <span class=\"mhh-mcn-v1-link__label\">Informazione professionale di KEYTRUDA\u00ae<\/span>\n                <\/a><\/div>\n\n\n<div class=\"mhh-mcn-v1-links mhh-mcn-v1-links--ce8dc5ff87cd02eab2851f710bb0637e\">\n    <a class=\"mhh-mcn-v1-link mhh-mcn-v1-link--7e8b20c3ff97e2e08e00a9609fa1992c mhh-mcn-v1-link--is-variation mhh-mcn-v1-link--button-primary\" href=\"https:\/\/www.mymsd.ch\/it\/succinctstatement\/keytruda\/\" target=\"_blank\" rel=\"noopener noreferrer\" aria-label=\"Informazione professionale breve di KEYTRUDA\u00ae\">\n                    <span class=\"mhh-mcn-v1-link__label\">Informazione professionale breve di KEYTRUDA\u00ae<\/span>\n                <\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Al congresso ESMO 2025 sono stati presentati numerosi progressi significativi nella ricerca sul cancro. Abbiamo riassunto per lei in modo sintetico i dati di follow-up dei nostri studi KEYNOTE.<\/p>\n","protected":false},"author":202221,"featured_media":104201,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"hide_header":false,"show_top_bar":false,"hide_footer":false,"full_width_layout":false,"icon":null,"job_code":"","hide_featured_image":true,"primary_tag":452,"editor_notices":[],"mconnectHideShareThis":false,"footnotes":"","sidebar_toogle":0,"sidebar_toogle_notification_warning":true,"sidebar_toogle_notification_alert":true,"content_expiration_sidebar_date":"","content_expiration_sidebar_expired_post_status":"","content_expiration_sidebar_redirection":""},"categories":[236],"tags":[452,226,419,425],"ga4_page_audience":[],"ga4_page_birn_id":[],"ga4_page_branding":[501],"ga4_page_businessunit":[507],"ga4_page_campaign":[],"ga4_page_content_purpose":[],"ga4_page_customer_journey_stage":[],"ga4_page_customer_specialty":[],"ga4_page_experience":[],"ga4_page_indication":[],"ga4_page_material_intent":[713],"ga4_page_product":[],"ga4_page_region":[],"ga4_page_therapeuticarea":[],"tx-therapeutic-area":[280,229],"tx-product":[270],"tx-pathology":[],"tx-content-type":[227],"tx-active-ingredient":[],"access":[],"user_status":[],"user_role":[],"class_list":["post-104200","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-onco-news-it","tag-congress-update","tag-keytruda","tag-melanoma","tag-nsclc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aggiornamento dall&#039;ESMO 2025 - MyMSD.ch IT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/follow-up-esmo-2025\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aggiornamento dall&#039;ESMO 2025 - MyMSD.ch IT\" \/>\n<meta property=\"og:description\" content=\"Al congresso ESMO 2025 sono stati presentati numerosi progressi significativi nella ricerca sul cancro. Abbiamo riassunto per lei in modo sintetico i dati di follow-up dei nostri studi KEYNOTE.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/follow-up-esmo-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"MyMSD.ch IT\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-18T20:42:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-02T14:38:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/11\/Teaser-ESMO-2025.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1149\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"MDM\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"MDM\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/follow-up-esmo-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/follow-up-esmo-2025\\\/\"},\"author\":{\"name\":\"MDM\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/#\\\/schema\\\/person\\\/5582d9c89a597dff94818e6008b86ab7\"},\"headline\":\"Aggiornamento dall\u2019ESMO 2025\",\"datePublished\":\"2025-11-18T20:42:45+00:00\",\"dateModified\":\"2026-03-02T14:38:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/follow-up-esmo-2025\\\/\"},\"wordCount\":290,\"publisher\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/follow-up-esmo-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/wp-content\\\/uploads\\\/sites\\\/47\\\/2025\\\/11\\\/Teaser-ESMO-2025.jpg\",\"keywords\":[\"Congress Update\",\"Keytruda\",\"Melanoma\",\"NSCLC\"],\"articleSection\":[\"Onco News IT\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/follow-up-esmo-2025\\\/\",\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/follow-up-esmo-2025\\\/\",\"name\":\"Aggiornamento dall'ESMO 2025 - MyMSD.ch IT\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/follow-up-esmo-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/follow-up-esmo-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/wp-content\\\/uploads\\\/sites\\\/47\\\/2025\\\/11\\\/Teaser-ESMO-2025.jpg\",\"datePublished\":\"2025-11-18T20:42:45+00:00\",\"dateModified\":\"2026-03-02T14:38:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/follow-up-esmo-2025\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/follow-up-esmo-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/follow-up-esmo-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/wp-content\\\/uploads\\\/sites\\\/47\\\/2025\\\/11\\\/Teaser-ESMO-2025.jpg\",\"contentUrl\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/wp-content\\\/uploads\\\/sites\\\/47\\\/2025\\\/11\\\/Teaser-ESMO-2025.jpg\",\"width\":1536,\"height\":1149,\"caption\":\"Image: ESMO 2025\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/oncology\\\/onco-news-it\\\/follow-up-esmo-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aggiornamento dall\u2019ESMO 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/#website\",\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/\",\"name\":\"MyMSD.ch IT\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/#organization\",\"name\":\"MSD Switzerland\",\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/wp-content\\\/uploads\\\/sites\\\/47\\\/2026\\\/11\\\/MSD-Logo-square.png\",\"contentUrl\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/wp-content\\\/uploads\\\/sites\\\/47\\\/2026\\\/11\\\/MSD-Logo-square.png\",\"width\":500,\"height\":500,\"caption\":\"MSD Switzerland\"},\"image\":{\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/#\\\/schema\\\/person\\\/5582d9c89a597dff94818e6008b86ab7\",\"name\":\"MDM\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/44e333b8caf35634006075d37ca161c6c10595fef18dfb504ce1f84b93d105fe?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/44e333b8caf35634006075d37ca161c6c10595fef18dfb504ce1f84b93d105fe?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/44e333b8caf35634006075d37ca161c6c10595fef18dfb504ce1f84b93d105fe?s=96&d=mm&r=g\",\"caption\":\"MDM\"},\"url\":\"https:\\\/\\\/www.mymsd.ch\\\/it\\\/author\\\/mdalmolin1\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aggiornamento dall'ESMO 2025 - MyMSD.ch IT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/follow-up-esmo-2025\/","og_locale":"it_IT","og_type":"article","og_title":"Aggiornamento dall'ESMO 2025 - MyMSD.ch IT","og_description":"Al congresso ESMO 2025 sono stati presentati numerosi progressi significativi nella ricerca sul cancro. Abbiamo riassunto per lei in modo sintetico i dati di follow-up dei nostri studi KEYNOTE.","og_url":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/follow-up-esmo-2025\/","og_site_name":"MyMSD.ch IT","article_published_time":"2025-11-18T20:42:45+00:00","article_modified_time":"2026-03-02T14:38:16+00:00","og_image":[{"width":1536,"height":1149,"url":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/11\/Teaser-ESMO-2025.jpg","type":"image\/jpeg"}],"author":"MDM","twitter_card":"summary_large_image","twitter_misc":{"Scritto da":"MDM","Tempo di lettura stimato":"3 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/follow-up-esmo-2025\/#article","isPartOf":{"@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/follow-up-esmo-2025\/"},"author":{"name":"MDM","@id":"https:\/\/www.mymsd.ch\/it\/#\/schema\/person\/5582d9c89a597dff94818e6008b86ab7"},"headline":"Aggiornamento dall\u2019ESMO 2025","datePublished":"2025-11-18T20:42:45+00:00","dateModified":"2026-03-02T14:38:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/follow-up-esmo-2025\/"},"wordCount":290,"publisher":{"@id":"https:\/\/www.mymsd.ch\/it\/#organization"},"image":{"@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/follow-up-esmo-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/11\/Teaser-ESMO-2025.jpg","keywords":["Congress Update","Keytruda","Melanoma","NSCLC"],"articleSection":["Onco News IT"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/follow-up-esmo-2025\/","url":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/follow-up-esmo-2025\/","name":"Aggiornamento dall'ESMO 2025 - MyMSD.ch IT","isPartOf":{"@id":"https:\/\/www.mymsd.ch\/it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/follow-up-esmo-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/follow-up-esmo-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/11\/Teaser-ESMO-2025.jpg","datePublished":"2025-11-18T20:42:45+00:00","dateModified":"2026-03-02T14:38:16+00:00","breadcrumb":{"@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/follow-up-esmo-2025\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/follow-up-esmo-2025\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/follow-up-esmo-2025\/#primaryimage","url":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/11\/Teaser-ESMO-2025.jpg","contentUrl":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2025\/11\/Teaser-ESMO-2025.jpg","width":1536,"height":1149,"caption":"Image: ESMO 2025"},{"@type":"BreadcrumbList","@id":"https:\/\/www.mymsd.ch\/it\/oncology\/onco-news-it\/follow-up-esmo-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mymsd.ch\/it\/"},{"@type":"ListItem","position":2,"name":"Aggiornamento dall\u2019ESMO 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.mymsd.ch\/it\/#website","url":"https:\/\/www.mymsd.ch\/it\/","name":"MyMSD.ch IT","description":"","publisher":{"@id":"https:\/\/www.mymsd.ch\/it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mymsd.ch\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/www.mymsd.ch\/it\/#organization","name":"MSD Switzerland","url":"https:\/\/www.mymsd.ch\/it\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.mymsd.ch\/it\/#\/schema\/logo\/image\/","url":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2026\/11\/MSD-Logo-square.png","contentUrl":"https:\/\/www.mymsd.ch\/it\/wp-content\/uploads\/sites\/47\/2026\/11\/MSD-Logo-square.png","width":500,"height":500,"caption":"MSD Switzerland"},"image":{"@id":"https:\/\/www.mymsd.ch\/it\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.mymsd.ch\/it\/#\/schema\/person\/5582d9c89a597dff94818e6008b86ab7","name":"MDM","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/secure.gravatar.com\/avatar\/44e333b8caf35634006075d37ca161c6c10595fef18dfb504ce1f84b93d105fe?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/44e333b8caf35634006075d37ca161c6c10595fef18dfb504ce1f84b93d105fe?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/44e333b8caf35634006075d37ca161c6c10595fef18dfb504ce1f84b93d105fe?s=96&d=mm&r=g","caption":"MDM"},"url":"https:\/\/www.mymsd.ch\/it\/author\/mdalmolin1\/"}]}},"_links":{"self":[{"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/posts\/104200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/users\/202221"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/comments?post=104200"}],"version-history":[{"count":13,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/posts\/104200\/revisions"}],"predecessor-version":[{"id":105151,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/posts\/104200\/revisions\/105151"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/media\/104201"}],"wp:attachment":[{"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/media?parent=104200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/categories?post=104200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tags?post=104200"},{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_audience?post=104200"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_birn_id?post=104200"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_branding?post=104200"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_businessunit?post=104200"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_campaign?post=104200"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=104200"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=104200"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=104200"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_experience?post=104200"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_indication?post=104200"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_material_intent?post=104200"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_product?post=104200"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_region?post=104200"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=104200"},{"taxonomy":"tx-therapeutic-area","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-therapeutic-area?post=104200"},{"taxonomy":"tx-product","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-product?post=104200"},{"taxonomy":"tx-pathology","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-pathology?post=104200"},{"taxonomy":"tx-content-type","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-content-type?post=104200"},{"taxonomy":"tx-active-ingredient","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/tx-active-ingredient?post=104200"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/access?post=104200"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/user_status?post=104200"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.mymsd.ch\/it\/wp-json\/wp\/v2\/user_role?post=104200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}